Transdermal Delivery of Vaccines and Therapeutic Proteins - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Transdermal Delivery of Vaccines and Therapeutic Proteins
The author reviews advances in technology that may soon allow transdermal delivery of two of the fastest growing drug classes on the pharmaceutical market. This article is part of a special Drug Delivery issue.


Pharmaceutical Technology
pp. s14-s20

References

1. E. N. Marieb and K. Hoehn, Human Anatomy & Physiology, (Benjamin Cummings, San Francisco, CA, 8th ed., 2010).

2. J. Nicolas and B. Guy, Expert Reviews Vaccine 7 (8), 1201–1214 (2008).

3. I. M. Braverman, JID Symposium Proceedings 5 (1), 3–9 (2000).

4. A. Laurent et al., Vaccine 25, 6423–6430 (2007).

5. M. Skobe and M. Detmar, JID Symposium Proceedings 5 (1), 14–19 (2000).

6. P. S. Mortimer et al., Jrnl. of Invest. Derm. 95 (6), 677–682 (1990).

7. D. Lubach, W. Ludemann, and D. Berens Von Rautenfeld, Br. J. Dermatol. 135 (5), 733–737 (1996).

8. J. Hickling and R. Jones, WHO PATH, 1–17 (Aug. 27, 2009).

9. G. Rozis et al., Immunology 124, 329–338 (2008).

10. L. Tuft, E.M. Yagle, and S. Rogers, Laboratories of the Graduate Hospital, University of Pennsylvania and the Research Institute of Cutaneous Medicine, pp. 99–110 (Apr. 20, 1931)

11. R. T. Kenney et al., The New Engl. Jrnl. of Med. 351 (22), 2295–2301 (2004).

12. K. J. Hansen and M. A, Tomai, "Highly Efficient Transdermal Delivery of Vaccines," presented at Modern Vaccine Adjuvants and Delivery Systems, Vienna, Austria, 2009.

13 S. K. Garg et al., Diabetes Technol. & Therapeut. 11, S5–S16, (2009)

14. S.A. Shoyele, and A. Slowey, Intern. Jrnl. of Pharmaceut. 314, 1–8, (2006)

15. K. Alitalo, T. Tammela, and T. V. Petrova, Nature 438 (15), 946–953 (2005).

16. M. S. Pepper and M. Skobe, Jrnl. of Cell Biol. 163 (2), 209–213 (2003).

17. W. N. Charman, V. J. Stella, Lymphatic Transport of Drugs, (CRS Press Inc, Boca Raton, FL, 1992)

18. L. V. Leak, Jrnl. of Cell Biol. 50, 300–323 (1971).

19. L.V. Leak and J. F. Burke, Am. J. Anat. 118, 785–810 (1966).

20. C. J. H. Porter and S. A. Charman, Jrnl. of Pharmaceut. Sci. 89 (3), 297–310 (2000).

21. A. Supersaxo et al., Pharm. Res. 5 (8), 472–476 (1988).

22. W. Morozowich et al., Proceed. Intern. Symp. Control. Rep. Bioact. Mater. 17, 185–186 (1990).

23. S. Mutanishi, T. Fujita, M. Mruakami, and A. Yamamoto, Jrnl. of Contr. Rel. 46, 157–164 (1997).


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
29%
Breakthrough designations
10%
Protecting the supply chain
43%
Expedited reviews of drug submissions
10%
More stakeholder involvement
10%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
Source: Pharmaceutical Technology,
Click here